Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Seamus Fernandez has reaffirmed a Buy rating on Apogee Therapeutics (NASDAQ:APGE) and increased the price target from $29 to $44.
January 03, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Seamus Fernandez maintains a Buy rating on Apogee Therapeutics and raises the price target from $29 to $44.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance and can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100